MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581381 | Name: Bismuth subcitrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bismuth subcitrate contains tripotassium di-citratobismuthate used in gastric & duodenal ulcer therapy. Bismuth subcitrate potassium is a bismuth salt used in combination with antibiotics and a proton pump inhibitor for the treatment of Helicobacter pylori infections.

Chemical Structure

Bismuth subcitrate
Bismuth subcitrate
CAS#57644-54-9

Theoretical Analysis

MedKoo Cat#: 581381

Name: Bismuth subcitrate

CAS#: 57644-54-9

Chemical Formula: C12H10BiK3O14

Exact Mass: 703.8786

Molecular Weight: 704.47

Elemental Analysis: C, 20.46; H, 1.43; Bi, 29.66; K, 16.65; O, 31.79

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Bismuth subcitrate; Duosol; Gastrodenol; Bismuth subcitrate potassium; De-Nol;
IUPAC/Chemical Name
Bismuth(3+) tripotassium bis(2-hydroxypropane-1,2,3-tricarboxylate)
InChi Key
ZQUAVILLCXTKTF-UHFFFAOYSA-H
InChi Code
InChI=1S/2C6H8O7.Bi.3K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;/q;;+3;3*+1/p-6
SMILES Code
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 704.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS, Pérez-Pérez G, Torres-López J, Abdo-Francis JM, Bielsa-Fernandez MV, Camargo MC, Esquivel-Ayanegui F, Garza-González E, Hernández-Guerrero AI, Herrera-Goepfert R, Huerta-Iga FM, Leal-Herrera Y, Lopéz-Colombo A, Ortiz-Olvera NX, Riquelme-Pérez A, Sampieri CL, Uscanga-Domínguez LF, Velarde-Ruiz Velasco JA. The fourth Mexican consensus on Helicobacter pylori. Rev Gastroenterol Mex. 2018 Jul - Sep;83(3):325-341. doi: 10.1016/j.rgmx.2018.05.003. Epub 2018 Jun 22. English, Spanish. PubMed PMID: 29941237. 2: Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PLoS One. 2018 Jun 11;13(6):e0197096. doi: 10.1371/journal.pone.0197096. eCollection 2018. PubMed PMID: 29889843; PubMed Central PMCID: PMC5995362. 3: Daghaghzadeh H, Memar A, Mohamadi Y, Rezakhani N, Safazadeh P, Aghaha S, Adibi P. Therapeutic Effects of Low-dose Bismuth Subcitrate on Symptoms and Health-related Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial. J Res Pharm Pract. 2018 Jan-Mar;7(1):13-21. doi: 10.4103/jrpp.JRPP_17_56. PubMed PMID: 29755994; PubMed Central PMCID: PMC5934982. 4: Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Scida S, Miraglia C, Penna A, Licci C, Rizzo GL, Pranzo G, Cassieri C, Brandimarte G, Picchio M, Di Mario F. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. Dig Dis. 2018;36(4):264-268. doi: 10.1159/000487391. Epub 2018 Apr 17. PubMed PMID: 29669354. 5: Sebghatollahi V, Soheilipour M, Khodadoostan M, Shavakhi A, Shavakhi A. Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. Adv Biomed Res. 2018 Mar 27;7:55. doi: 10.4103/abr.abr_133_17. eCollection 2018. PubMed PMID: 29657940; PubMed Central PMCID: PMC5887790. 6: Li L, Meng F, Zhu S, Guo S, Wang Y, Zhao X, Sun Y, Zhang Y, Wang Q, Xu H, Zhang S. Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori. Evid Based Complement Alternat Med. 2018 Feb 5;2018:4320219. doi: 10.1155/2018/4320219. eCollection 2018. PubMed PMID: 29636776; PubMed Central PMCID: PMC5832115. 7: Pellicano R, Zagari RM, Zhang S, Saracco GM, Moss SF. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018 Sep;64(3):310-321. doi: 10.23736/S1121-421X.18.02492-3. Epub 2018 Mar 30. PubMed PMID: 29600697. 8: Liu Y, Shen C, Zhang X, Yu H, Wang F, Wang Y, Zhang LW. Exposure and nephrotoxicity concern of bismuth with the occurrence of autophagy. Toxicol Ind Health. 2018 Mar;34(3):188-199. doi: 10.1177/0748233717746810. Epub 2018 Mar 5. Review. PubMed PMID: 29506455. 9: Wang R, Lai TP, Gao P, Zhang H, Ho PL, Woo PC, Ma G, Kao RY, Li H, Sun H. Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors. Nat Commun. 2018 Jan 30;9(1):439. doi: 10.1038/s41467-018-02828-6. PubMed PMID: 29382822; PubMed Central PMCID: PMC5789847. 10: Yang X, Koohi-Moghadam M, Wang R, Chang YY, Woo PCY, Wang J, Li H, Sun H. Metallochaperone UreG serves as a new target for design of urease inhibitor: A novel strategy for development of antimicrobials. PLoS Biol. 2018 Jan 10;16(1):e2003887. doi: 10.1371/journal.pbio.2003887. eCollection 2018 Jan. PubMed PMID: 29320492; PubMed Central PMCID: PMC5779714. 11: Ye JF, Hong JB, Zhu Y, Xie Y, Shu X, Luo LY, Xie C, Zhu ZH, Lu NH. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. J Dig Dis. 2017 Dec;18(12):704-708. doi: 10.1111/1751-2980.12559. PubMed PMID: 29119724. 12: Pérez-Arellano E, Rodriguez-Garcia MI, Galera Rodenas AB, de la Morena-Madrigal E. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. Gastroenterol Hepatol. 2018 Mar;41(3):145-152. doi: 10.1016/j.gastrohep.2017.08.005. Epub 2017 Oct 18. English, Spanish. PubMed PMID: 29054320. 13: Omouri Z, Hawari J, Fournier M, Robidoux PY. Bioavailability and chronic toxicity of bismuth citrate to earthworm Eisenia andrei exposed to natural sandy soil. Ecotoxicol Environ Saf. 2018 Jan;147:1-8. doi: 10.1016/j.ecoenv.2017.08.018. Epub 2017 Aug 16. PubMed PMID: 28822260. 14: Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00140-17. doi: 10.1128/AAC.00140-17. Print 2017 Nov. PubMed PMID: 28807915; PubMed Central PMCID: PMC5655074. 15: Wu MC, Wang YK, Liu CJ, Yu FJ, Kuo FC, Liu ML, Kuo CH, Wu DC, Huang YK, Wu IC. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol Res Pract. 2017;2017:5320180. doi: 10.1155/2017/5320180. Epub 2017 Jul 16. PubMed PMID: 28791044; PubMed Central PMCID: PMC5534286. 16: Li CY, Wu C. Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers. Inflammopharmacology. 2018 Apr;26(2):337-347. doi: 10.1007/s10787-017-0380-x. Epub 2017 Jul 22. PubMed PMID: 28735449. 17: Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J Dig Dis. 2017 Sep;18(9):537-542. doi: 10.1111/1751-2980.12498. PubMed PMID: 28644575. 18: Mansour-Ghanaei F, Pedarpour Z, Shafaghi A, Joukar F. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication. Middle East J Dig Dis. 2017 Apr;9(2):100-106. doi: 10.15171/mejdd.2017.58. PubMed PMID: 28638586; PubMed Central PMCID: PMC5471100. 19: Gómez Rodríguez BJ, Castro Laria L, Argüelles Arias F, Castro Márquez C, Caunedo Álvarez Á, Romero Gómez M. A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. Rev Esp Enferm Dig. 2017 Aug;109(8):552-558. doi: 10.17235/reed.2017.4809/2016. PubMed PMID: 28617030. 20: Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab J Gastroenterol. 2017 Jun;18(2):62-67. doi: 10.1016/j.ajg.2017.05.002. Epub 2017 Jun 7. PubMed PMID: 28601610.